According to the report published in Nature magazine in January 2019, NL-201 (Neoleukin-2/15; Neo-2/15), developed by Neoleukin Therapeutics, is the first computationally designed de novo CD25-independent IL-2/IL-15 receptor agonist that specifically boosts the proliferation and tumor infiltration of NK and CD8+ T lymphocytes, thus improving antitumor performance (53). This evidence concerns the gene IL2 and neoplasm.